Sales 2024 * | 185M 253M | Sales 2025 * | 251M 344M | Capitalization | 376M 514M |
---|---|---|---|---|---|
Net income 2024 * | -12M -16.4M | Net income 2025 * | 23M 31.43M | EV / Sales 2024 * | 2.04 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.5 x |
P/E ratio 2024 * |
-33
x | P/E ratio 2025 * |
17.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.42% |
Latest transcript on Imprimis Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Andrew Boll
DFI | Director of Finance/CFO | 41 | 11-11-30 |
Jamie Webb
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Director/Board Member | 65 | 01-25 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 01-25 |
1st Jan change | Capi. | |
---|---|---|
+29.68% | 681B | |
+19.95% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+13.58% | 235B | |
+4.42% | 199B | |
-12.39% | 189B | |
-3.79% | 157B |